Neurologists and the economics of MS treatment
Lighting candles, not cursing the darkness
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
It is understandable that neurologists might “curse the darkness” that engulfs the economics of multiple sclerosis (MS) care. The price of MS disease-modifying therapies (DMTs) is shocking. In 2013, the average wholesale price of all MS DMTs in the United States clustered around $65,000 a year and prices continue to increase by more than 10% per year.1 In response to skyrocketing DMT prices, insurance companies and specialty pharmacies create rules regulating coverage of MS treatments with little input from neurologists.2 Neurologists must navigate Kafkaesque health insurance bureaucracies to obtain coverage for treatments we deem appropriate for our patients. By contrast, reimbursements for neurologists illustrate that we may be undervalued. In 2013, Medicare spent $820 million for a single MS DMT, glatiramer acetate, which nearly equaled the $939 million paid to all neurologists for their evaluation and management services.3 Neurologists, the experts in the care of MS, have no influence over the rising cost of DMTs or the decisions made by the health insurance industry regarding coverage of therapies. Frustrated neurologists complain at meetings and via e-mail groups about medication cost and lack of influence, generating much heat but little light.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 1617
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Author response to Dr. Otulana
- Dennis N. Bourdette, Chair and Professor, Department of Neurology, Oregon Health & Science Universitybourdett@ohsu.edu
Submitted April 27, 2017 - Response to "Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness"
- Tunde Otulana, SVP, Chief Medical Officer, Mallinckrodt Pharmaceuticalstunde.otulana@mallinckrodt.com
Submitted April 27, 2017
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan